The path to blockbuster sales for Travere's Filspari will start with a gradual ramp into 2028, Evercore ISI analysts predict. (bluejayphoto/iStock/Getty Images Plus ...
If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure “Today marks an important milestone in our mission to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results